FDA 483 - OrBion Pharmaceuticals Private Limited - October 27, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
OrBion Pharmaceuticals Private Limited in Sriperumbudur, India, was cited for significant deficiencies in its quality control and laboratory practices. The inspection revealed a lack of established procedures to prevent objectionable microorganisms in non-sterile drug products, leading to fungal contamination and uninvestigated microbial growth. Additionally, laboratory records were incomplete, with uncounted microbial growth and the use of defective media compromising test integrity.
ID · c77d5f8a-9fe4-4f3a-9420-8cb38c1c0df4